SCHEMBL1616342

SCHEMBL1616342

O=C1C(Br)CCCC1c1ccccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.41
RECQL P46063 1/20 0.41
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
ALOX15 P16050 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA1B P35368 1/20 0.35
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
HTR2B P41595 2/20 0.35
HRH3 Q9Y5N1 2/20 0.35
KDM4E B2RXH2 1/20 0.35
SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1617328 0.98 TP53 (0.40) TP53RECQLALDH1A1GAASMN1; SMN2
SCHEMBL1615843 0.81 HTR1A (0.38) TP53RECQLALDH1A1GAAALOX15
SCHEMBL1617043 0.81 GAA (0.42) TP53ALDH1A1GAAHTR2AHTR2C
SCHEMBL23471602 0.80 TP53 (0.41) TP53RECQLALDH1A1GAASMN1; SMN2
SCHEMBL20993884 0.80 TP53 (0.41) TP53RECQLALDH1A1GAASMN1; SMN2
SCHEMBL14866651 0.80 TP53 (0.41) TP53RECQLALDH1A1GAASMN1; SMN2
SCHEMBL23352419 0.80 TP53 (0.41) TP53RECQLALDH1A1GAASMN1; SMN2
SCHEMBL19400507 0.80 TP53 (0.41) TP53RECQLALDH1A1GAASMN1; SMN2
SCHEMBL19403923 0.80 TP53 (0.41) TP53RECQLALDH1A1GAASMN1; SMN2
SCHEMBL25771258 0.78 TP53 (0.39) TP53RECQLALDH1A1SMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012030952-A3 REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY TEXAS INSTRUMENTS INCORPORATED (US) 2012-05-10 WO disclosed
EP-2231629-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2011-11-30 EP disclosed
US-7923450-B2 Modulators for amyloid beta HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2231629-A1 MODULATORS FOR AMYLOID BETA F. Hoffmann-La Roche AG (CH) 2010-09-29 EP disclosed
WO-2009087127-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 WO disclosed
US-20090181965-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181965-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, BACE1 TP53 1297/4885RECQL 60/4885ALDH1A1 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.